{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:29:46Z","timestamp":1788953386930,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the absence of an adequate prevention strategy, up to 20% of CMV IgG+\u2009liver transplant recipients (LTR) will develop CMV disease. Despite improved reporting in CMV-DNAemia, there is no consensus as to what the ideal CMV-DNAemia cutoff for a successful preemptive strategy is. Each transplant centre establishes their own threshold. We aimed to determine the effectiveness of our preventive strategy in CMV IgG+\u2009LTR, and evaluate CMV replication kinetics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective study we determined the incidence of CMV disease in the first 6\u00a0months following transplantation in CMV seropositive LTR in a tertiary-care centre in Mexico. Secondary outcomes were determining the number of patients who required preemptive therapy (treatment cutoff\u2009\u2265\u20094000 UI\/ml), adherence to the centre\u2019s prevention protocol and calculation of viral replication kinetics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One-hundred and twenty-four patients met inclusion criteria. Four patients (3.2%) developed CMV disease. Ninety-six (85%) had detectable DNAemia and 25 (22%) asymptomatic patients received preemptive therapy, none of them developed CMV disease. The highest viral loads were observed on the second posttransplant month. The number of viral load measurements decreased over time. Patients with DNAemia\u2009\u2265\u20094000 UI\/ml had a faster viral load growth rate, shorter viral load duplication time, and higher basic reproductive number. Viral load growth rate and autoimmune hepatitis were associated with development of DNAemia\u2009\u2265\u20094000 UI\/ml.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Cytomegalovirus disease occurred in 3.2% of the study subjects. Preemptive therapy using a threshold of CMV\u2009\u2265\u20094000 UI\/ml was effective in reducing the incidence of end-organ disease. The viral replication parameters described in this population highlight the importance of frequent monitoring, a challenging feat for transplant programs in low- and middle-income countries.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07123-w","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T13:03:11Z","timestamp":1644843791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Oscar A.","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Francisco","family":"Belaunzar\u00e1n-Zamudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Vilatoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wisniowski-Y\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Salom\u00f3n-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bobadilla-del-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Sifuentes-Osornio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Cuellar-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"issue":"9","key":"7123_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","volume":"98","author":"M Stern","year":"2014","unstructured":"Stern M, Hirsch H, Cusini A, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98(9):1013\u20138.","journal-title":"Transplantation"},{"issue":"4","key":"7123_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1128\/CMR.00015-13","volume":"26","author":"R Razonable","year":"2003","unstructured":"Razonable R, Hayden R. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2003;26(4):703\u201327.","journal-title":"Clin Microbiol Rev"},{"key":"7123_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1086\/340653","volume":"185","author":"V Emery","year":"2002","unstructured":"Emery V, Hassan-Walker A, Burroughs A, Griffiths P. Human cytomegalovirus (HCMV) replication dynamics in HCMV-Na\u00efve and\u2014experienced immunocompromised hosts. J Infect Dis. 2002;185:1723\u20138.","journal-title":"J Infect Dis"},{"key":"7123_CR4","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","volume":"12","author":"S Atabani","year":"2012","unstructured":"Atabani S, Smith C, Atkinson C, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 2012;12:2457\u201364.","journal-title":"Am J Transplant"},{"issue":"1","key":"7123_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcv.2012.09.017","volume":"56","author":"C Martin-Gandul","year":"2013","unstructured":"Martin-Gandul C, Perez-Romero P, Sanchez M, et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients al lower risk of CMV infection. J Clin Virol. 2013;56(1):13\u20138.","journal-title":"J Clin Virol"},{"issue":"1","key":"7123_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch H, et al. Definitions of cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2017;64(1):87\u201391.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"7123_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bpg.2012.01.004","volume":"26","author":"B van Hoek","year":"2012","unstructured":"van Hoek B, de Rooij B, Verspaget H. Risk factors for infection after liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26(1):61\u201372.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"7123_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1600-6143.2005.01176.x","volume":"6","author":"P Pappas","year":"2006","unstructured":"Pappas P, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant. 2006;6(2):386\u201391.","journal-title":"Am J Transplant"},{"key":"7123_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133960","author":"E Duke","year":"2020","unstructured":"Duke E, Williamson B, Borate B, et al. Cytomegalovirus viral load kinetics as surrogate endpoints after allogeneic transplantation. J Clin Invest. 2020. https:\/\/doi.org\/10.1172\/JCI133960.","journal-title":"J Clin Invest"},{"issue":"4","key":"7123_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/cid\/cix793","volume":"66","author":"Y Natori","year":"2018","unstructured":"Natori Y, Alghamadi A, Tazari M, et al. Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(4):617\u201331.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"7123_CR11","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1128\/JCM.00316-13","volume":"51","author":"A Limaye","year":"2013","unstructured":"Limaye A, Santo Hayes T, Huang M-L, et al. Quantitation of cytomegalovirus viral load in dried blood spots correlated well with plasma viral load. J Clin Microbiol. 2013;51(7):2360\u20134.","journal-title":"J Clin Microbiol"},{"key":"7123_CR12","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1086\/514145","volume":"176","author":"A Cope","year":"1997","unstructured":"Cope A, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis. 1997;176:1484\u201390.","journal-title":"J Infect Dis"},{"issue":"12","key":"7123_CR13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/archsurg.1989.01410120093018","volume":"124","author":"R Stratta","year":"1989","unstructured":"Stratta R, Shaefer M, Markin R, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg. 1989;124(12):1443\u20139.","journal-title":"Arch Surg"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07123-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07123-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07123-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T13:04:47Z","timestamp":1644843887000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07123-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7123"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07123-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"26 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were conducted in accordance with the Declaration of Helsinki. It was approved by the Research Ethics Committee of the Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n (Project ID Number INF-2254-17-18-1), the committee waived the need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}